Shanghai Pharmaceuticals released its 2026 interim report. Total operating revenue was 147.47 billion yuan, up 4.15% year-on-year, while net profit attributable to the parent company was 3.504 billion yuan, down 21.40% year-on-year. Net cash inflow from operating activities was 4.45 billion yuan, up 349.78% year-on-year. The company's asset-liability ratio was 61.46%, gross margin was 11.03%, ROE was 4.47%, and diluted earnings per share was 0.95 yuan. The number of shareholders was 95,300, and the top ten shareholders held 90.50% of the shares.
Shanghai Pharmaceuticals Holding Co LtdNet profit down 21.40% year-on-year despite revenue growth.
